



www.mgcpharma.com.au

Company Profile & MGC Derma Case Study



This presentation has been prepared by MGC Pharmaceuticals Limited ("Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and

prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.


Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

An Australian company Listed since 2016

MGC Pharmaceuticals (ASX:MXC) is a European focused Bio-Pharma company, developing a vertically integrated business through the entire Phytomedicines value chain
A complete "Seed to Pharma" strategy applicable to multiple verticals.



MGC Pharmaceuticals (ASX:MXC) is a European focused Bio-Pharma company, developing a vertically integrated business through the whole Phytomedicines value chain - a complete "Seed to Pharma" strategy

Capital Structure

ASX code	MXC
Market capitalisation (as at 123/11/2018)	~A\$50m
Share price - as at 30 September 2018	4.1c
Cash at Bank – as at 30 September 2018	~A\$8.5m

Issued Capital

Ordinary shares	1,212m
Listed Options (6.5c, expiring 30/6/19)	91.3m
Performance Shares and Rights	103.7m
Unlisted Options (12.5c, expiring 31/3/21)	20.5m
Unlisted Options (15.0c, expiring 30/6/21)	10.0m

Share Registry

Computershare Investor Services Pty Limited
Level 11, 172 St Georges Terrace,
Perth WA 6000

Lead Corporate Advisor:

Chieftain Securities

Auditors


PKF Mack
Level 4,
35 Havelock Street,
West Perth WA 6005

Solicitors

Steinepreis Paganin
Level 4, The Read Buildings
16 Milligan Street,
Perth WA 6000

HOLDINGS

- Management
- Key supporters
- Institutions
- Retail



Our Vision

To solidify our position as a global leader in Phytocannabinoid-based medicines within the biopharmaceutical industry.

MGC Pharma's goal is to facilitate the transformation of Phytocannabinoids into true medicinal product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients' lives.

Our Mission

Building a global supply chain focused on creating final medicinal products and improving the lives of patients, by developing ground-breaking treatments through innovative research across multiple markets.

MGC Pharma is at the forefront of research and development in this exploding market, with the potential to supply its products to research efforts worldwide, and then to the markets that this research opens.

MGC Pharma engages with multiple cultivation sites to meet increasing global demand, alongside research into breeding and genetics with leading institutions and academia

**Greenhouse facility
in Czech Republic
+1,000m²**

Second cycle of Panax harvested, yielding over 600kg of high CBD and THC flowers

Biomass will be processed into CBD crystals for use in the Company's MGC Pharma and MGC Derma product lines



**Open Field Farm and
Collaborative Partnerships
in Slovenia +4,000m²**

Genetic research program underway to isolate strains with specific levels cannabinoids to be integrated into the Company's R&D and product pipeline.

4,000m² open field Hemp cultivation for raw materials



**Collaborative Partnerships
in Slovenia**

University of Ljubljana

Genetic research program underway to create genetic strains with high levels of CBD and THC for the treatment of specific disease symptoms.

Medicinal cannabis seeds planted in June 2017 for the project.

IHPS

The Slovenian Institute of Hop Research and Brewing


Collaboration with IHPS, Ljubljana, to cultivate strains for global export.



University of Ljubljana
Biotechnical Faculty

R&D and IP are the Company's keys to future success. Bringing together the most experienced and curious minds from around the world, to target and provide formulations for the most pressing medical issues which can be addressed with phytocannabinoids today, is crucial to product development and corporate growth.

The core of MGC's Seed to Pharma strategy is focused on medical research and development of the Company's pharmaceutical product pipeline, which will provide raw materials and appropriately matched genetics to treat patients with a variety of diseases across the globe.



University of Ljubljana
Biotechnical Faculty



NATIONAL INSTITUTE OF BIOLOGY



MGC Pharma's core strategy revolves around fully integrated in house "Seed to Pharma" operations with EU centered facilities, focused on the production of pharmaceutical products supported by ongoing research and development activities

- █ Holds an euGMP certified production facility for the development and manufacturing Phytomedicines.
- █ Clinical Trials program for EMA registration is underway, with near term revenues thru special prescribers schemes in Australia and Europe.
- █ Robust R&D platform and positioning, based on more than 10 years accrued experience in phytocannabinoid research, patient interaction and product formulation in the global market.
- █ Led by a strong Executive Management team and Advisory Board, with years of experience in clinical research and conducting successful human trials with Phytomedicines.
- █ Unique ability of its advisory board to implement clinical studies via active European, Australian and Israeli collaborative academic and commercial relationships.
- █ Core strategy includes production, research and development of unique phytocannabinoid pharmaceutical products, alongside the production of Active Pharmaceutical Ingredient (API) of various cannabinoids, emerging from a self contained pipeline that runs from cultivation through extraction.
- █ Near term retail activities through CannaGlobal, a Canadian growth-focused global cannabis aggregator, with large retail reach and experience, uniquely structured for scalable growth beyond traditional markets.

MGC Pharmaceuticals (ASX:MXC) is leveraging unique R&D capabilities and IP to create a global Bio-Pharma company focused on development of phytocannabinoid based medications.



Emerging from a pharmaceutical grade pipeline, MGC Nutraceuticals provides premium Cannabis Sativa L. (Hemp) based products that create balance and wellness within users' internal systems.

Pharmaceutical Grade Nutraceuticals & Product Formulation

Promoting inner health and wellbeing, MGC Nutraceuticals’ product range includes multiple premium products, comprising supplements and food grade products in flavours such as forest fruit, blueberry and vanilla.

The products contain high grade phytocannabinoids, which have been grown, extracted and processed under the Company’s strict quality control guidelines and standards, alongside natural vegan proteins and vitamins.



Mabsut Life, a -multi-year binding agreement to supply cannabidiol (CBD) extract to European distributor, operating in Germany, the Czech Republic and Austria



MGC Nutraceuticals

eCommerce website launching soon.


To coincide with the launch, the release of a new product catalogue and new e-commerce website supporting the MGC Nutraceuticals range is now live.



Visit <http://www.mgcnutraceuticals.com/>

\$561 billion USD
global nutraceuticals market by 2020¹

1. <https://www.mordorintelligence.com/industry-reports/global-nutraceuticals-market-industry>



\$675 Billion USD
Global cosmetics market by 2020¹

Product launch in
North America and Asean
planned for 2019



1. ResearchAndMarkets, June 2015



To change the perception of Cannabis based cosmetic products, globally, and to be the first choice of those whose perception we change...

Our Values — Quality, Innovation, Changing Paradigms, Making Skin Healthy & Beautiful, Early to Market




Cannabis and Cosmetics: Where Ancient Knowledge meets Modern Science

When applied topically to the skin, **CBD stimulates activity** in the body's Endocannabinoid System alongside reduction in free radical's existence, which encourages the skin's own response, encouraging **repair** and **rejuvenation**.

In addition, Cannabinoids assist to neutralize the harmful free radicals that bombard our skin from UV sources, such as the sun, which cause ageing, cancer and impaired healing. In this way, **Cannabinoids protect the skin** from long-lasting damage.

CBD also works to **increase the rate of absorption** of other compounds into the skin, so that together with its own properties, the use of CBD in topical cosmeceutical applications results in healthier, protected, more youthful-looking skin and makes it the ideal basis for a new era of groundbreaking, effective, cosmetic treatments.





Derma Plus

Dermatological products which undergo strict, volunteer based clinical tests, the Derma Plus line represents the true value of Phytocannabinoid based skin treatments: **proven success and impact on users wellbeing.**



Herbal Repair Cream

Skin condition improvement

Psoriatic plaques - 73%
Rough skin - 63%
Inflamed skin - 63%
Itching skin - 69%



Herbal Replenish Cream

Skin condition improvement

Dry skin - 71%
Irritated / inflamed skin - 86%
Flaking skin - 65%
Itching skin - 86%



Herbal Repair Balm

Skin condition improvement

Oily skin - 96%
Acne prone skin - 80%
Papulose skin - 72%

The following calculated values present the percentage of improvement in skin conditions after 30 days

Due the results, 92 % of patients would continue using the tested products.

Testing performed at the highest standards:


Regulation of the European Parliament and of the Council (EC) No. 1223/2009 of 30 November 2009 on cosmetic products. Cosmetics Europe – The Personal Care Association (previously COLIPA) Guidelines Product Test Guidelines for the Assessment of Human Skin Compatibility 1997. Cosmetics Europe – The Personal Care Association (previously COLIPA) Guidelines for the Evaluation of the Efficacy of Cosmetic Products 2008.

MGC Derma's LMS

The MGC Derma Learning Management System (LMS) is a platform that was created to educate and assist the staff of MGC Derma distributors. Through the LMS system, people can learn, and be tested on MGC Derma products, as well as Cannabis in general.

All of the information provided in the LMS is written succinctly, in an easy to understand way so staff can get the information they need. By knowing more about the products and what goes into them, staff can provide better information about MGC Derma products to customers, meaning they will be more effective at converting sales.

lms.mgcderma.com



Operational Structure

MGC Derma is composed of two divisions:

Production and Sales

- Existing product lines
- Expanding markets
- Customer feedback and requests
- Support for dealers and white label

Research and Development

- Clinical Studies
- New Product Development (inhouse and third party)
- White Label Support






MGC Derma Achievements

- Clinical studies on over 90 volunteers with overwhelming results
- Established major EU distribution channels
- LMS Implementation
- 100% Cruelty Free
- CPNP Certified
- GMP & ISO Certified



Media and Press



 REFINERY29

ELLE

BAZAAR

STYLENEST

MGC Pharma has recently vended it's MGC Derma division into CannaGlobal

CannaGlobal is a Canadian company established by high profile cannabis entrepreneur Lorne Gertner, whose track record in both retail and cannabis has created the most suitable vehicle for development of a brand like MGC Derma



A diversified, growth focused holding company with a global portfolio of cannabis assets in markets worldwide. Structured around four strategic cornerstones consolidation, connection, culture and creation – its mandate is to explore and capitalize on exceptional cannabis opportunities in international markets that are disruptive



Holding unique IP which places the Company at the forefront of Phytomedicines research and development within large and growing global markets



- euGMP certification granted for the production and compounding of Phyto-cannabinoids based Investigational Medicinal Products (IMP).

- MGC Facilities are a unique facility in Europe, allowing the development of further Phyto-cannabinoids based medications.



- CannEpiL™ is a Phyto-cannabinoids based product used for drug-resistant epilepsy, (otherwise known as refractory), to be provided to patients in Australia via the Authorized Prescriber Scheme.

- The products price point and efficacy will make it a viable alternative to current therapies.



- Landmark. Collaboration agreement signed between MGC RMIT and the Hebrew University to establish the “CannaHub”.

- Establishing the Cannabis Medicine Library, and focusing on pre-clinical research on melanoma and prostate cancer”.

- Currently developing CannEpiL™ App for patient monitoring.



- Strategic Alliance with Australia’s leading Epilepsy association, Epilepsy Action Australia (EAA).

- MGC products will be introduced by the EAA to its members in accordance with their medical requirements.

- Collaboration on developing C4E campaign to increase awareness and access to Cannabis based Medications.



Evidence has shown that the market for diseases medical cannabis can treat will grow significantly in the coming years.

MGC Pharma R&D products pipeline is divided into the following groups:

Neurological Disorders	Oncological	Autoimmune Anti-inflammatory	Other Indications
<p>Epilepsy The global epilepsy medication market is approximately US\$3.7B</p>	<p>Glioblastoma The global Glioblastoma Multiform (GGM) market should reach US\$1.15B in 2024</p>	<p>Seborrhea Dermatitis The global atopic dermatitis (AD) market is expected to grow to US\$7.66B in 2025 from US\$4.04B in 2016</p>	<p>Crohn's Disease The global inflammatory bowel diseases (IBD) market is expected to reach US\$9.5B in 2020 from US\$8.5B in 2016</p>
<p>Dementia The global dementia medication market is approximately US\$14B</p>	<p>Melanoma The global melanoma medication market should reach US\$4.71B by end of 2022 from US\$2.04B in 2016</p>	<p>Fibromyalgia & Chronic Pain The market is expected to rise from a valuation of US\$60.2B in 2015 to US\$83.0B by 2024</p>	<p>Cachexia The global cancer therapeutics market should reach US\$172.6B by 2022 from US\$121B in 2017</p>
<p>Autism Autism is a fragmented US\$5.5B market in the US</p>	<p>Prostate The global prostate cancer therapeutics market size was valued at US\$7.9 billion in 2016</p>	<p>Psoriasis The global market for psoriasis treatment, should reach US\$12.1B by 2024 from US\$7.8B in 2015</p>	<p>IBS The global therapeutics market for Irritable Bowel Syndrome is expected to reach US\$1.5B by 2023 from US\$589.6M in 2013</p>

CannEpiTM is a Cannabinoid-based IMP used as a treatment for refractory epilepsy

Neurological Disorders

Epilepsy

The global epilepsy medication market is approximately US\$3.7B.

Production Commenced

Authorized by the TGA to prescribe in Australia.

MGC Pharma's European medicinal cannabis manufacturing facility has completed production of the first batch of CannEpiTM, following receipt of its GMP certification.

CannEpiTM is MGC's first pharmaceutical-grade medical cannabis product targeted for drug resistant (refractory) epilepsy, which accounts for approximately 30% of the estimated 240,000 people diagnosed with epilepsy in Australia each year.

CannEpiTM

CannEpiTM is an oral oil solution of cannabidiol (CBD) and (-)- trans- Δ^9 -tetrahydrocannabinol (THC).

CannEpiTM is produced from two proprietary, preselected, specifically bred Genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.

1ml of CannEpiTM contains 100mg CBD and 5mg THC. Beside THC and CBD, CannEpiTM contains a minor amount of additional specific cannabinoids and terpenes from cannabis plant that are working synergistically with CBD and THC to maximize the efficiency.



MGC Pharma is developing pharmaceutical grade products that leverage the Company's own proprietary medical cannabis formula through successful clinical trials in Europe, Australia and Israel.

This enables future medical product sales across the European Union, Australia and other geographies, following the requisite legal and regulatory approvals.

Neurological Symptoms and Disorders

CannEpi™ Treatment of Adult Refractory Epilepsy	Authorized for A.P. by the TGA
CannEpi™ Epilepsy Seizure Reduction In Youth and Adolescents	Pending Phase II in Europe
CogniCann™ Treatment of Dementia	Phase 2 – Patient recruitment early 2019

Oncological & Cancer Side Effects

Tetrinol™ Treatment of Anorexia Cachexia in Cancer Patients	Preclinical in progress
MXOT02GB01 Treatment of Glioblastoma (NIB)	Preclinical in progress
MXOT02ME01 Treatment of Melanoma (RMIT)	Preclinical in progress

Autoimmune Disease - Inflammatory

Refurbish Cream Topical Treatment of Seborrheic Dermatitis	Preclinical results: Reduction 70% in 4 w.
--	--

Other indications

MXAD02CD01 Treatment of Crohn's Disease	Preclinical finished
---	----------------------



Thank You

info@mgcpharma.com.au
www.mgcpharma.com.au